2021
respiratory webcast series
2021 Respiratory Webcast Series
The past year has seen the implementation of new recommendations for asthma and COPD treatment from the Asthma and Respiratory Foundation NZ and the GINA 2021 Report. At the same time, COVID-19 imposed new requirements upon doctor-patient consultations and protocols. We are pleased to host a series of webcasts throughout the year, focusing on what these things mean for practitioners and patients, and discussing the latest treatment options. Find out more about the first event of the series and register by clicking on the link below.
Asthma & Respiratory Foundation NZ COPD Guidelines – Updated for 2021 with Dr Stuart Jones, Respiratory and General Physician at Middlemore Hospital, Auckland, NZ
Thursday, 27th May 2021 at 6:30 pm (45 minutes + questions)
Dr Stuart Jones Respiratory and general physician at Middlemore Hospital, Auckland, NZ. MBChB (Otago 1995), PhD (Otago 2003), FRACP (2007)
Dr. Stuart Jones originates from the far north, however headed to the far south attending Otago Medical School from which he graduated in 1995. He spent his initial post-graduate years working at Dunedin Hospital before taking up a post as respiratory research fellow at the Dunedin School of Medicine. In 2003 he graduated with a PhD from Otago University with a thesis entitled: Exhaled nitric oxide and the clinical control of airway inflammation. He commenced his respiratory specialist training in Dunedin before heading to the UK for a further 3 years of training. During his time in the UK he was based in Cambridge where he worked at the local university hospital (Addenbrookes) and at Papworth Hospital, a specialist cardio-respiratory unit. While at Papworth he trained in pulmonary hypertension and sleep medicine. He then went to Edinburgh where he worked as a sleep fellow at the Royal Infirmary. He is currently employed as a respiratory and general physician at Middlemore Hospital. He specialises in general respiratory medicine, with a particular interest in sleep medicine, asthma and airway inflammation, and pulmonary hypertension.
To Register, Please Scan
or
CLICK HERE
This webcast has been initiated, organised and funded by AstraZeneca. The content is intended for registered HealthCare Professionals for educational purposes. The company seeks no commitment from external stakeholders to take any action as a result of the invitation or related support. PRIVACY STATEMENT: Your personal information (“Information”) will be collected and used by AstraZeneca Pty Ltd (“AstraZeneca”) for the purpose of administration of the webcast, for follow-up purposes and for any other purpose described in AstraZeneca’s Privacy Policy (see below for link). AstraZeneca may disclose your Information to third parties such as our related entities or service providers (including IT support/ service providers), some of which may be located overseas including in the US, European Union and Asia Pacific. Please refer to our Privacy Policy (https://www.astrazeneca.com.au/ privacy-policy.html) for more information about how your Information is handled and how you may seek to access or correct your Information. If you have any queries about how we handle your personal information, please write to: Privacy Officer, AstraZeneca, PO Box 131, North Ryde, NSW, 1670, Australia or email to: privacy.au@astrazeneca.com. AstraZeneca Limited, PO Box 87453, Meadowbank, Auckland 1742. For Medical Information enquiries or to report an adverse event or product quality complaint: Telephone (09) 306 5650 or via https://contactazmedical.astrazeneca.com Or email Medical Information enquiries to medinfo.nz@astrazeneca.com. NZ-1373, TAPS NA 12964, E-011435, May 2021.